William P. Melega, Ph.D.

Titles

Professor, Biomedical Physics IDP
Semel Institute for Neuroscience and Human Behavior
Professor in Residence, Molecular & Medical Pharmacology
Member, Brain Research Institute
Molecular Pharmacology GPB Home Area
Neuroscience GPB Home Area
Faculty, Molecular Toxicology IDP

Contact Information

Email
wmelega@mednet.ucla.edu
Phone
Lab Number: (310) 206-8811
Address
Work Address: OfficeBRILos Angeles, CA 90095UNITED STATES

Publications:

Melega WP, Lacan G, Gorgulho AA, Behnke EJ, De Salles AA   Hypothalamic deep brain stimulation reduces weight gain in an obesity-animal model PLoS ONE , 2012; 7(1): e30672, 1-8.
Yong J, Lacan G, Dang H, Hsieh T, Middleton B, Wasserfall C, Tian J, Melega WP, Kaufman DL   BCG vaccine-induced neuroprotection in a mouse model of Parkinson's Disease PLoS ONE, 2011; 6(1): e16610.
Kuczenski R, Segal DS, Melega WP, Lacan G, McCunney SJ   Human methamphetamine pharmacokinetics simulated in the rat: behavioral and neurochemical effects of a 72-hour binge Neuropsychopharmacology, 2009; 34: 2430Ė2441.
Lacan G, Plenevaux A, Rubins D, Way BM, Defraiteur C, Gillet S, Lemaire C, Aerts J, Luxen, A, Cherry SR, Melega WP.   Cyclosporine, a p-glycoprotein modulator, increases 18F-MPPF binding in rat brain and peripheral tissues: Micropet and ex vivo studies, Eur. J. Nuc. Med. Mol. Imaging, 2008; .
Chin MH, Qian W-J, Wang H, Petyuk VA, Bloom JS, Sforza DM, Lacan G, Liu D, Khan AH, Cantor RM, Bigelow DJ, Melega WP, Camp II DG, Richard D. Smith RD, Smith DJ.   miRNAs and codon usage regulate striatal gene and protein expression in two mouse models of Parkinson's disease, J Proteome Res, 2008; 7: 666-677.
Melega WP, Cho AK, Harvey DC, Lacan G   Methamphetamine blood concentrations in human abusers: application to pharmacokinetic modeling, Synapse, 2007; 61: 216-220.
O'Neil ML,Kuczenski R, Segal DS, Cho AK, Lacan G, Melega WP   Escalating dose pretreatment induces pharmacodynamic and not pharmacokinetic tolerance to a subsequent high-dose methamphetamine binge, Synapse, 2006; 60: 465-473.
Segal, DS Kuczenski, R O'Neil, ML Melega, WP Cho, AK   Prolonged exposure of rats to intravenous methamphetamine: behavioral and neurochemical characterization Psychopharmacology, 2005; 180(3): 501-12.
Segal DS, Kuczenski R, O'Neil ML, Melega WP, Cho AK   Prolonged exposure of rats to intravenous methamphetamine: behavioral and neurochemical characterization, Psychopharmacology (Berl), 2005; 180: 501-512.
Rubins, DJ Melega, WP Lacan, G Way, B Plenevaux, A Luxen, A Cherry, SR   Development and evaluation of an automated atlas-based image analysis method for microPET studies of the rat brain NeuroImage, 2003; 20(4): 2100-18.
Segal DS, Kuczenski R, ONeil ML, Melega WP, Cho AK.   Escalating dose methamphetamine pretreatment alters the behavioral and neurochemical profiles associated with exposure to a high dose methamphetamine binge, Neuropsychopharmacology, 2003; 28: 1730-40.
Cho AK, Melega WP   Patterns of methamphetamine abuse and their consequences Journal of addictive diseases , 2002; 21(1): 21-34.
Brown, VM Ossadtchi, A Khan, AH Yee, S Lacan, G Melega, WP Cherry, SR Leahy, RM Smith, DJ   Multiplex three-dimensional brain gene expression mapping in a mouse model of Parkinson's disease Genome research, 2002; 12(6): 868-84.
Cho, AK Melega, WP Kuczenski, R Segal, DS   Relevance of pharmacokinetic parameters in animal models of methamphetamine abuse Synapse (New York, N.Y.) , 2001; 39(2): 161-6.
Harvey, DC Lacan, G Tanious, SP Melega, WP   Recovery from methamphetamine induced long-term nigrostriatal dopaminergic deficits without substantia nigra cell loss Brain research. , 2000; 871(2): 259-70.
Cho, AK Melega, WP Kuczenski, R Segal, DS Schmitz, DA   Caudate-putamen dopamine and stereotypy response profiles after intravenous and subcutaneous amphetamine Synapse (New York, N.Y.) , 1999; 31(2): 125-33.
Melega, WP Cho, AK Schmitz, D Kuczenski, R Segal, DS   l-methamphetamine pharmacokinetics and pharmacodynamics for assessment of in vivo deprenyl-derived l-methamphetamine The Journal of pharmacology and experimental therapeutics, 1999; 288(2): 752-8.